YURAK-QON TOMIR KASALLIKLARINING RIVOJLANISHIDA METABOLIK VA GEMODINAMIK OMILLARNING O‘ZARO TA’SIRI

Dillayev Abdurahmon Shamsiddin o'g'li; Berdimurodov Javlonbek Xayrulla o’gli; O'rinov Adhamjon Akramovich

Authors

Dillayev Abdurahmon Shamsiddin o'g'li Samarqand Davlat Tibbiyot Universiteti DKTF terapiya, kardiologiya va funksional diagnostika kafedrasi klinik ordinatori
Berdimurodov Javlonbek Xayrulla o’gli Samarqand Davlat Tibbiyot Universiteti DKTF terapiya, kardiologiya va funksional diagnostika kafedrasi klinik ordinatori
O'rinov Adhamjon Akramovich Samarqand Davlat Tibbiyot Universiteti DKTF terapiya, kardiologiya va funksional diagnostika kafedrasi klinik ordinatori

Keywords:

Yurak-qon tomir kasalliklari, metabolik omillar, gemodinamik o‘zgarishlar, arterial gipertoniya, dislipidemiya, insulin rezistentligi, miokard remodelatsiyasi, yurak yuklamasi.

Abstract

Ushbu maqolada yurak-qon tomir kasalliklarining rivojlanishida metabolik va gemodinamik omillarning o‘zaro ta’siri chuqur tahlil qilinadi. Metabolik buzilishlar, xususan dislipidemiya, insulin rezistentligi va semizlik kabi holatlarning yurak faoliyatiga ta’siri gemodinamik o‘zgarishlar bilan uzviy bog‘liqligi yoritib beriladi. Shuningdek, arterial bosimning oshishi, yurak yuklamasining ortishi va miokard strukturasidagi funksional o‘zgarishlarning patogenetik mexanizmlari ko‘rib chiqiladi. Maqolada zamonaviy ilmiy manbalar asosida metabolik va gemodinamik omillarning o‘zaro ta’siri yurak-qon tomir patologiyalarining og‘irlashishiga qanday ta’sir ko‘rsatishi tahlil qilinadi. Tadqiqot natijalari yurak kasalliklarini erta aniqlash, samarali davolash va individual profilaktika strategiyalarini ishlab chiqishda muhim ahamiyat kasb etadi.

References

1. Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. 11th ed. Philadelphia: Elsevier; 2019.

2. Libby P., Bonow R.O., Mann D.L., Zipes D.P. Braunwald’s Heart Disease: Review and Assessment. Elsevier; 2020.

3. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–3104.

4. Grundy S.M., Cleeman J.I., Daniels S.R. et al. Diagnosis and management of the metabolic syndrome. Circulation. 2005;112(17):2735–2752.

5. Messerli F.H., Rimoldi S.F., Bangalore S. The transition from hypertension to heart failure. Journal of the American College of Cardiology. 2017;70(6):716–726.

6. Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction. Lancet. 2004;364(9438):937–952.

7. McMurray J.J.V., Pfeffer M.A. Heart failure. Lancet. 2005;365(9474):1877–1889.